HealthCor Catalio Acquisition Corp. (HCAQ) News
Filter HCAQ News Items
HCAQ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HCAQ News Highlights
- HCAQ's 30 day story count now stands at 2.
- Over the past 7 days, the trend for HCAQ's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest HCAQ News From Around the Web
Below are the latest news stories about HealthCor Catalio Acquisition Corp that investors may wish to consider to help them evaluate HCAQ as an investment opportunity.
Hyperfine Closes Business Combination with HealthCor Catalio Acquisition Corp and Liminal Sciences, Will Begin Trading under the Ticker "HYPR" on the Nasdaq Global MarketHyperfine Inc., the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it has completed its business combination with HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ) ("HealthCor"), a special purpose acquisition company sponsored by leading healthcare funds HealthCor Management, L.P. and Catalio Capital Management, LP, and Liminal Sciences, Inc. ("Liminal"), a medical device development company dedicated to non-in |
HealthCor Catalio Acquisition Corp. Reminds Shareholders to Vote in Favor of the Business Combination with Hyperfine, Inc. and Liminal Sciences, Inc.HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ) ("HealthCor") reminds its shareholders to vote at the upcoming extraordinary general meeting of HealthCor's shareholders (the "Special Meeting") on December 21, 2021 to, among other matters, approve the proposed business combination with Hyperfine, Inc. ("Hyperfine") and Liminal Sciences, Inc. ("Liminal") and, in connection therewith, HealthCor's change of domicile to Delaware (the "Domestication"). |
Moore Kuehn Encourages CND, HCAQ, HCCC and FPAC Investors to Contact Law FirmMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: |
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of HealthCor Catalio Acquisition Corp. (Nasdaq - HCAQ)BALA CYNWYD, PA / ACCESSWIRE / July 8, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of HealthCor Catalio Acquisition Corp. ("HealthCor Catalio" or the "Company") (Nasdaq - HCAQ) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which HealthCor Catalio, a special purpose acquisition company, will combine with Hyperfine, Inc. |
Hyperfine, Inc., Creator of the First FDA-Cleared Portable MRI Device, and Liminal Sciences, Inc. To Be Listed on Nasdaq Through a Business Combination With HealthCor Catalio Acquisition Corp.GUILFORD, Conn., July 08, 2021--Hyperfine, Inc. and Liminal Sciences, Inc. to be listed on Nasdaq through a business combination with HealthCor Catalio Acquisition Corp. |
HealthCor Catalio Acquisition Corp. Announces Closing of Upsized $207 Million Initial Public OfferingHealthCor Catalio Acquisition Corp. (the "Company"), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses, today announced the closing of its upsized initial public offering of 20,700,000 Class A ordinary shares at a price of $10.00 per share, including 2,700,000 Class A ordinary shares issued pursuant to the underwriter's full exercise of its over-allotment option. Total gross proceeds from the offering were $207 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company. |